Dianthus Therapeutics (DNTH) Stock Forecast, Price Target & Predictions
DNTH Stock Forecast
Dianthus Therapeutics stock forecast is as follows: an average price target of $51.00 (represents a 76.10% upside from DNTH’s last price of $28.96) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
DNTH Price Target
The average price target for Dianthus Therapeutics (DNTH) is $51.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $51.00 to $51.00. This represents a potential 76.10% upside from DNTH's last price of $28.96.
DNTH Analyst Ratings
According to 5 Wall Street analysts, Dianthus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DNTH stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Dianthus Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 18, 2024 | Steven Seedhouse | Raymond James | $51.00 | $24.15 | 111.18% | 76.10% |
The latest Dianthus Therapeutics stock forecast, released on Apr 18, 2024 by Steven Seedhouse from Raymond James, set a price target of $51.00, which represents a 111.18% increase from the stock price at the time of the forecast ($24.15), and a 76.10% increase from DNTH last price ($28.96).
Dianthus Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $51.00 |
| Last Closing Price | $28.96 | $28.96 | $28.96 |
| Upside/Downside | -100.00% | -100.00% | 76.10% |
In the current month, the average price target of Dianthus Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Dianthus Therapeutics's last price of $28.96. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 12, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 12, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 27, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| May 16, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Apr 18, 2024 | Raymond James | Outperform | Outperform | Hold |
| Nov 22, 2023 | Wedbush | - | Outperform | Initialise |
| Dec 21, 2022 | BTIG | Buy | Buy | Hold |
| Jan 06, 2022 | Goldman Sachs | - | Buy | Upgrade |
Dianthus Therapeutics's last stock rating was published by Wedbush on Aug 12, 2024. The company gave DNTH a "Buy" rating, the same as its previous rate.
Dianthus Therapeutics Financial Forecast
Dianthus Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $924.00K |
| Avg Forecast | $472.60K | $472.60K | $472.60K | $472.60K | $598.29K | $598.29K | $368.86K | $464.25K | $548.50K | $250.00K |
| High Forecast | $472.60K | $472.60K | $472.60K | $472.60K | $598.29K | $1.01M | $368.86K | $464.25K | $728.83K | $250.00K |
| Low Forecast | $472.60K | $472.60K | $472.60K | $472.60K | $598.29K | $271.95K | $368.86K | $464.25K | $225.41K | $250.00K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.70% |
Dianthus Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $548.50K, with a low forecast of $225.41K, and a high forecast of $728.83K. DNTH's average Quarter revenue forecast represents a -40.64% decrease compared to the company's last Quarter revenue of $924.00K (Sep 23).
Dianthus Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-15.74M |
| Avg Forecast | $-94.52K | $-94.52K | $-94.52K | $-94.52K | $-119.66K | $-119.66K | $-73.77K | $-92.85K | $-109.70K | $-50.00K |
| High Forecast | $-94.52K | $-94.52K | $-94.52K | $-94.52K | $-119.66K | $-54.39K | $-73.77K | $-92.85K | $-45.08K | $-50.00K |
| Low Forecast | $-94.52K | $-94.52K | $-94.52K | $-94.52K | $-119.66K | $-202.33K | $-73.77K | $-92.85K | $-145.76K | $-50.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | 314.87% |
undefined analysts predict DNTH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Dianthus Therapeutics's previous annual EBITDA (undefined) of $NaN.
Dianthus Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $-14.76M |
| Avg Forecast | $-26.08M | $-26.63M | $-26.08M | $-23.82M | $-23.31M | $-20.95M | $-18.66M | $-14.99M | $-32.17M | $-19.17M |
| High Forecast | $-26.08M | $-26.63M | $-26.08M | $-23.82M | $-23.31M | $-18.21M | $-18.66M | $-14.99M | $-30.14M | $-19.17M |
| Low Forecast | $-26.08M | $-26.63M | $-26.08M | $-23.82M | $-23.31M | $-25.08M | $-18.66M | $-14.99M | $-37.68M | $-19.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.77% |
Dianthus Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DNTH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Dianthus Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $8.72M |
| Avg Forecast | $1.01M | $1.01M | $1.01M | $1.01M | $1.28M | $1.28M | $787.59K | $991.27K | $1.17M | $533.80K |
| High Forecast | $1.01M | $1.01M | $1.01M | $1.01M | $1.28M | $2.16M | $787.59K | $991.27K | $1.56M | $533.80K |
| Low Forecast | $1.01M | $1.01M | $1.01M | $1.01M | $1.28M | $580.67K | $787.59K | $991.27K | $481.30K | $533.80K |
| Surprise % | - | - | - | - | - | - | - | - | - | 16.34% |
Dianthus Therapeutics's average Quarter SG&A projection for Dec 23 is $1.17M, based on 3 Wall Street analysts, with a range of $481.30K to $1.56M. The forecast indicates a -86.57% fall compared to DNTH last annual SG&A of $8.72M (Sep 23).
Dianthus Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-3.78 |
| Avg Forecast | $-0.76 | $-0.78 | $-0.76 | $-0.70 | $-0.68 | $-0.61 | $-0.55 | $-0.44 | $-0.94 | $-0.56 |
| High Forecast | $-0.76 | $-0.78 | $-0.76 | $-0.70 | $-0.68 | $-0.53 | $-0.55 | $-0.44 | $-0.88 | $-0.56 |
| Low Forecast | $-0.76 | $-0.78 | $-0.76 | $-0.70 | $-0.68 | $-0.73 | $-0.55 | $-0.44 | $-1.10 | $-0.56 |
| Surprise % | - | - | - | - | - | - | - | - | - | 6.75% |
According to undefined Wall Street analysts, Dianthus Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DNTH previous annual EPS of $NaN (undefined).
DNTH Forecast FAQ
Is Dianthus Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Dianthus Therapeutics (DNTH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of DNTH's total ratings.
What is DNTH's price target?
Dianthus Therapeutics (DNTH) average price target is $51 with a range of $51 to $51, implying a 76.10% from its last price of $28.96. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Dianthus Therapeutics stock go up soon?
According to Wall Street analysts' prediction for DNTH stock, the company can go up by 76.10% (from the last price of $28.96 to the average price target of $51), up by 76.10% based on the highest stock price target, and up by 76.10% based on the lowest stock price target.
Can Dianthus Therapeutics stock reach $40?
DNTH's average twelve months analyst stock price target of $51 supports the claim that Dianthus Therapeutics can reach $40 in the near future.
What are Dianthus Therapeutics's analysts' financial forecasts?
Dianthus Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.03M (high $2.44M, low $1.7M), average EBITDA is $-406K (high $-341K, low $-489K), average net income is $-77.92M (high $-75.172M, low $-82.042M), average SG&A $4.33M (high $5.22M, low $3.64M), and average EPS is $-2.277 (high $-2.196, low $-2.397). DNTH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.89M (high $1.89M, low $1.89M), average EBITDA is $-378K (high $-378K, low $-378K), average net income is $-103M (high $-103M, low $-103M), average SG&A $4.04M (high $4.04M, low $4.04M), and average EPS is $-2.998 (high $-2.998, low $-2.998).
Did the DNTH's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Sep 2023), Dianthus Therapeutics's revenue was $924K, beating the average analysts' forecast of $250K by 269.60%. The company's EBITDA was $-15.743M, beating the average prediction of $-49.999K by 31386.63%. Dianthus Therapeutics's net income was $-14.763M, missing the average estimation of $-19.167M by -22.98%. The company's SG&A was $8.72M, beating the average forecast of $533.8K by 1534.12%. Lastly, the company's EPS was $-3.78, beating the average prediction of $-0.56 by 575.00%